Myokardia Inc (NASDAQ:MYOK) insider Anastasios Gianakakos sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $51.05, for a total transaction of $153,150.00. Following the transaction, the insider now owns 77,390 shares in the company, valued at $3,950,759.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Anastasios Gianakakos also recently made the following trade(s):

  • On Thursday, January 4th, Anastasios Gianakakos sold 3,000 shares of Myokardia stock. The stock was sold at an average price of $41.70, for a total transaction of $125,100.00.
  • On Thursday, December 21st, Anastasios Gianakakos sold 3,000 shares of Myokardia stock. The stock was sold at an average price of $41.09, for a total transaction of $123,270.00.

Shares of Myokardia Inc (NASDAQ:MYOK) opened at $47.50 on Friday. Myokardia Inc has a 12 month low of $10.80 and a 12 month high of $55.40.

Several institutional investors and hedge funds have recently bought and sold shares of MYOK. Nationwide Fund Advisors raised its stake in shares of Myokardia by 36.3% during the second quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock worth $127,000 after buying an additional 2,591 shares during the last quarter. Alliancebernstein L.P. bought a new stake in Myokardia in the second quarter valued at approximately $148,000. SG Americas Securities LLC bought a new stake in Myokardia in the fourth quarter valued at approximately $185,000. The Manufacturers Life Insurance Company increased its stake in Myokardia by 38.8% in the second quarter. The Manufacturers Life Insurance Company now owns 15,073 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 4,215 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Myokardia in the third quarter valued at approximately $202,000. 63.82% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts have recently issued reports on MYOK shares. Zacks Investment Research upgraded shares of Myokardia from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. TheStreet lowered shares of Myokardia from a “c” rating to a “d+” rating in a research report on Friday, November 3rd. ValuEngine lowered shares of Myokardia from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. JPMorgan Chase & Co. started coverage on shares of Myokardia in a research report on Tuesday, December 12th. They set an “overweight” rating and a $54.00 target price on the stock. Finally, BidaskClub raised shares of Myokardia from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Myokardia currently has an average rating of “Buy” and a consensus price target of $55.67.

TRADEMARK VIOLATION NOTICE: This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2018/02/10/insider-selling-myokardia-inc-myok-insider-sells-3000-shares-of-stock.html.

Myokardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Insider Buying and Selling by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.